PharmaCyte Biotech (Formerly Known As Nuvilex)
1971 Old Cuthbert Road
Cherry Hill
New Jersey
08034
United States
Tel: 856-433-6088
Fax: 856-354-1077
Website: http://www.nuvilex.com/
Email: info@nuvilex.com
375 articles about PharmaCyte Biotech (Formerly Known As Nuvilex)
-
PharmaCyte Biotech Announces Closing of $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
8/23/2021
PharmaCyte Biotech, Inc. today announced the closing of its previously announced registered direct offering priced at-the-marked under Nasdaq rules, of 14,000,000 shares of the Company’s common stock
-
PharmaCyte Biotech Announces $70 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
8/19/2021
PharmaCyte Biotech, Inc. today announced that it has entered into definitive agreements with institutional investors for the purchase and sale, in a registered direct offering priced at-the-marked under Nasdaq rules.
-
PharmaCyte Biotech Releases Statement on Nasdaq Uplisting and Current Business Focus
8/16/2021
PharmaCyte Biotech Releases Statement on Nasdaq Uplisting and Current Business Focus
-
PharmaCyte Biotech Announces Closing of $15-Million Public Offering
8/12/2021
PharmaCyte Biotech, Inc. today announced the closing of its previously announced underwritten public offering of approximately $15 million.
-
PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering
8/9/2021
PharmaCyte Biotech, Inc., a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced that the Company’s common stock is expected to begin trading on The Nasdaq Capital Market on August 10, 2021, under the symbol “PMCB.” The Company also announced the pricing of its previously announced underwritten public offering.
-
PharmaCyte Biotech Announces Uplist to The Nasdaq Capital Market and Launch of Public Offering
8/2/2021
PharmaCyte Biotech, Inc. (OTCQB: PMCBD) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that The Nasdaq Stock Market LLC (Nasdaq) has approved the listing of the Company’s common stock on Nasdaq.
-
PharmaCyte Biotech Provides Update to Nasdaq Listing Efforts and Presents Scientific Publications Supporting Pancreatic Cancer Treatment
7/22/2021
PharmaCyte Biotech, Inc. (OTCQB: PMCBD), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that three independent industry publications mention PharmaCyte and/or its past clinical trials and their contributions to prior and future work in the treatment of pancreatic cancer.
-
PharmaCyte Biotech Announces Update on Study Progress and Uplist to Nasdaq
7/14/2021
PharmaCyte Biotech, Inc. today announced that the production and shipping of test materials and study plan designs for the biocompatibility studies requested by the U.S. Food and Drug Administration (FDA) have been completed.
-
PharmaCyte Biotech Announces Stability Test Results on Cells from Master Cell Bank
7/12/2021
PharmaCyte Biotech, Inc. today announced that after 3 years of storage in a vapor phase of liquid nitrogen, the original cytochrome P450 expressing cells from PharmaCyte’s Master Cell Bank (MCB) manufactured by Eurofins Lancaster Laboratories continue to retain their viability and excellent enzymatic activity, both of which are critical stability parameters.
-
PharmaCyte Biotech Announces Reverse Stock Split
7/10/2021
PharmaCyte Biotech, Inc., a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced that it will effect a 1-for-1,500 reverse stock split of its shares of common stock, leaving the Company with only about 1.6 million issued and outstanding shares.
-
PharmaCyte Biotech Announces Results of Vote at Annual Meeting of Stockholders
7/8/2021
PharmaCyte Biotech, Inc. today announced that all 4 proposals presented to the Company’s stockholders for a vote at the 2021 Annual Meeting of Stockholders have passed.
-
PharmaCyte Biotech Provides Update on Status of Activities to Lift Clinical Hold
6/24/2021
PharmaCyte Biotech, Inc. today announced the efforts being undertaken by the Company to have the U.S. Food and Drug Administration (FDA) clinical hold lifted.
-
PharmaCyte Biotech Announces Shareholders Vote to Increase the Authorized Capital
6/22/2021
PharmaCyte Biotech, Inc. announced today that, unofficially, a majority of PharmaCyte’s shareholders have voted in favor of Proposal No. 2, the proposal to increase the authorized number of shares of its common stock.
-
PharmaCyte Biotech Announces Adjournment of Annual Meeting of Stockholders, Recording of Stockholder Meeting Available
6/18/2021
PharmaCyte Biotech, Inc., a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced that its 2021 Annual Meeting of Stockholders, held on June 16, 2021, has been adjourned until June 30, 2021, at 11:00 a.m.
-
PharmaCyte Biotech Announces Details to Attend This Week’s Virtual Annual Meeting of Shareholders
6/14/2021
PharmaCyte Biotech Announces Details to Attend This Week’s Virtual Annual Meeting of Shareholders
-
PharmaCyte Biotech Successfully Completes 1 Year Stability Study
4/1/2021
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has successfully completed the twelve-months product stability testing required by the U.S. Food and Drug Administration (FDA) for its CypCaps™ final clinical trial product.
-
PharmaCyte Biotech Begins DNA Sequence and Stability Studies in Response to FDA Requests for its Clinical Trial Product
1/26/2021
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has commenced additional studies to determine the exact sequence of the DNA encoding of the enzyme in the cells of its CypCaps ® product for pancreatic cancer
-
PharmaCyte Biotech Begins Physical Testing of CypCaps in Response to FDA Recommendations for its Clinical Trial Product
12/14/2020
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has commenced additional physical parameter testing of its CypCaps ® product for pancreatic cancer, in line with the recommendations provided by the U.S. Food and Drug Administration (FDA).
-
PharmaCyte Biotech Successfully Completes 9-Month Stability Study
12/2/2020
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has successfully completed the nine-months product stability testing that is required by the U.S. Food and Drug Administration (FDA) for its CypCaps™ final product, which will be used in the co
-
PharmaCyte Biotech Receives U.S. FDA Clinical Hold Letter
11/4/2020
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has received the clinical hold letter from the U.S. Food and Drug Administration (FDA) with respect to its Investigational New Drug Application (IND)